ImmunoGen Stock Jumps Following Ovarian Cancer Study Results

© Reuters.

By Sam Boughedda — ImmunoGen Inc (NASDAQ:) stock jumped at the open today after it announced positive results from its trial of mirvetuximab soravtansine in ovarian cancer.

Notably, the SORAYA trial met its primary endpoint with a confirmed objective response rate of 32.4%.

ImmunoGen shares are currently up over 37%.

The company said it aims to complete the Biologics License Application for mirvetuximab, its potential treatment for patients with platinum-resistant ovarian cancer, by submitting an application to the Food and Drug Administration for accelerated approval in the first quarter of 2022.

Mark Enyedy, ImmunoGen’s president and CEO, said it is an “exciting moment, both for the field of ovarian cancer and for ImmunoGen,” with the outcomes from the SORAYA trial “further validate our longstanding history of innovation in ADCs.” 

“Commercial preparations are well underway to support the potential launch of mirvetuximab next year,” he added.


Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.